SRAM
ANIK icon

Stone Ridge Asset Management’s Anika Therapeutics ANIK Stock Holding History

Stone Ridge Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-7,378
Closed -$248K – 1116
2018
Q4 		$248K Sell
7,378
-3,625
-33% -$131K 0.02% 1062
2018
Q3 		$464K Buy
11,003
+2,836
+35% +$112K 0.02% 889
2018
Q2 		$261K Buy
8,167
+480
+6% +$19.8K 0.01% 1082
2018
Q1 		$382K Hold
7,687
– – 0.02% 919
2017
Q4 		$414K Buy
+7,687
New +$425K 0.03% 902

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Stone Ridge Asset Management's ANIK Position: Q1 2019 in Review

Stone Ridge Asset Management sold out of Anika Therapeutics (ANIK) in Q1 2019, closing a stake of 7,378 shares — an estimated $248K sold.

Stone Ridge Asset Management first reported a position in ANIK in Q4 2017 and held it in 5 quarters. The position peaked at $464K in Q3 2018. 157 funds tracked by Wall St. Rank hold ANIK as of Q1 2019.

  • Stone Ridge Asset Management reported no remaining Anika Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Stone Ridge Asset Management sold 7,378 Anika Therapeutics shares in Q1 2019, an estimated $248K.
  • Stone Ridge Asset Management first reported a position in Anika Therapeutics in Q4 2017 and held it in 5 quarters.
  • Stone Ridge Asset Management's Anika Therapeutics position peaked at $464K in Q3 2018.
  • 157 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2019.

Based on Stone Ridge Asset Management's 13F filing for Q1 2019, filed 14 May 2019.